CD19 and B-cell acute lymphoblastic leukemia: Published data indicate that CD19-negative relapse occurs in 7-25% of B-cell acute lymphoblastic leukemia (B-ALL) cases and approximately 30% of large B-cell lymphoma (LBCL) cases in patients treated with CD19 CAR therapy (4, 44–46).